Thomas Powles

TL;DR: Targeted therapies that have yielded the most promising results alone or combined with traditional chemotherapy, including the antiangiogenesis agent bevacizumab, the human epidermal growth factor receptor 2 antibody trastuzumAB, and the tyrosine kinase inhibitor cabozantinib are focused on.

TL;DR: Four cycles of platinum based, first line chemotherapy appeared adequate and did not significantly compromise the survival of patients with advanced urothelial carcinoma, suggesting the omission of excessive cycles may avoid unnecessary cumulative toxicity and facilitate a better transition to second line therapy and investigational switch maintenance therapy strategies.

TL;DR: PROs in IMmotion151 suggest lower overall treatment burden with atezolizumab plus bevacIZumab compared with sunitinib in patients with treatment-naïve mRCC and provide further evidence for clinical benefit of this regimen.

TL;DR: It is suggested that the higher risk of COVID-19 death associated with systemic therapy in cancer may not apply to patients on immune checkpoint inhibitors (ICIs), as this case series followed up patients with genitourinary cancer on ICI.